CHF Solutions

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

 Nuwellis

EDEN PRAIRIE, Minn., May 11, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (previously CHF Solutions, Inc.) announced today its results for the first quarter ended March 31, 2021, which included the following highlights:

Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update

EDEN PRAIRIE, Minn., April 29, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), formally CHF Solutions, announces today that its first quarter 2021 financial results will be released on Tuesday, May 11, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.

Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021

EDEN PRAIRIE, Minn., April 23, 2021 (GLOBE NEWSWIRE) -- Improving access to life-saving fluid management therapies is a commitment CHF Solutions (Nasdaq: CHFS) stands by. The company today announced Aquadex SmartFlow® is now available at two new pediatric hospitals in Texas. CHF Solutions is a medical device company dedicated to changing the lives of patients suffering from fluid overload.

CHF Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Two Texas Hospitals

New Clinical Abstract Available Online During National Kidney Foundation Spring Clinical Meeting (NKF) New Clinical Abstract Available Online During National Kidney Foundation Spring Clinical Meeting (NKF)

The Portability of Aquadex SmartFlow® from CHF Solutions Could Mean More Critically-Ill Patients Have Access to Life-Saving Ultrafiltration Therapy

EDEN PRAIRIE, Minn., March 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the closing of its previously announced underwritten public offering of 3,795,816 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $20.9 million, including the full exercise of the underwriters' over-allotment option to purchase additional shares of the Company's common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.

CHF Solutions, Inc. Announces Closing of $20.9 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

EDEN PRAIRIE, Minn., March 17, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the pricing of an underwritten public offering of 3,300,710 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $18.1 million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters an option, exercisable in whole or in part for 45 days, to purchase up to an additional 495,106 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

CHF Solutions, Inc. Announces Pricing of $18.1 Million Underwritten Public Offering of Common Stock

EDEN PRAIRIE, Minn., March 16, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by the Company.  The Company intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.  The Company intends to use the net proceeds for the offering for general corporate purposes, including the continued investment in commercialization efforts. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

CHF Solutions, Inc. Announces Proposed Underwritten Public Offering of Common Stock

EDEN PRAIRIE, Minn., March 11, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a system to dramatically improve and simplify venous access for Aquadex™ ultrafiltration and for multiple continuous renal replacement (CRRT) therapy modalities. The new system is intended to make CRRT therapies available to all patients through simple, safe, and easy-to-use peripheral venous access.

CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems

EDEN PRAIRIE, Minn., March 05, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, effective February 17, 2021, the independent directors approved one equity award under CHF Solution's New-Hire Equity Incentive Plan, as material inducement to an individual entering into employment with the company. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EDEN PRAIRIE, Minn., March 04, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, will participate in the first ERAS Cardiac Society Virtual Conference, broadcasting Live from Methodist Hospital DeBakey Center in Houston, Texas on March 5-6, 2021.

ERAS 2021: CHF Solutions to Host On-Demand Presentation on Management of Fluid Overload in Cardiac Surgery Patients

CHF Solutions' (CHFS) CEO Nestor Jaramillo on Q4 2020 Results - Earnings Call Transcript

CHF Solutions Inc (NASDAQ: CHFS) shares were trading higher Tuesday after the company released better-than-expected fourth-quarter earnings results. This caused a spike in volume as well as an increase in price in Tuesday's premarket and regular sessions.

CHF Solutions Trading On Increased Volume After Q4 Beat: Technical Levels To Watch

The stock price of CHF Solutions Inc (NASDAQ: CHFS) is trading at over 15% pre-market. This is why it happened.

CHFS Stock Price Increases Over 15% Pre-Market: Why It Happened

Shares of CHF Solutions (NASDAQ:CHFS) moved higher by 4.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 0.89% year over year to ($1.13), which beat the estimate of ($1.26).

CHF Solutions: Q4 Earnings Insights

EDEN PRAIRIE, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from its physician-led webinar discussing real-world experience using ultrafiltration (UF) in the management of heart failure patients. Panelists discussed results from the real-world retrospective study of 335 consecutive patients treated with the Aquadex FlexFlow® System, published in Journal of Cardiac Failure Supplement , that demonstrated UF compares favorably in reducing heart failure rehospitalizations, renal function response, and weight/volume loss.

CHF Solutions' Physician-Led Webinar Highlights Real-World Evidence Supporting Effectiveness of Ultrafiltration in Heart Failure Patients

EDEN PRAIRIE, Minn., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, physician-led webinar to discuss “Real-World Experience Using Ultrafiltration in the Management of Heart Failure Patients.” The virtual event will take place on Wednesday, January 27 at 11 a.m. Central Time.

CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients

EDEN PRAIRIE, Minn., Jan. 12, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a peripheral vascular access catheter for use with its Aquadex™ system. The new dual lumen ultrafiltration catheter optimizes blood flow, prevents kinking, and is customizable for each patient, eliminating the need for multiple catheter sizes.

CHF Solutions Protects New Peripheral Vascular Access Catheter with Patent Application

EDEN PRAIRIE, Minn., Dec. 04, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that Ladenburg Thalman & Co. will host a conference call and webcast at 1:00p.m. Eastern Time on Tuesday, December 8, 2020 highlighting pediatric ultrafiltration therapy and the Aquadex SmartFlow™ System as part of Ladenburg Thalman's LT Healthcare Symposia Series.

CHF Solutions Announces Webinar on Pediatric Ultrafiltration Therapy hosted by Ladenburg Thalman & Co.

CHF Solutions, Inc. (CHFS) CEO John Erb on Q3 2020 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the third quarter ended September 30, 2020.

CHF Solutions, Inc. Announces 52 Percent Increase in Revenue for Third Quarter 2020 and Provides Company Update

EDEN PRAIRIE, Minn., Nov. 03, 2020 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS) announces today that its third quarter 2020 financial results will be released on Tuesday, November 10, 2020. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.

CHF Solutions, Inc. To Announce Third Quarter 2020 Financial Results on November 10, 2020

EDEN PRAIRIE, Minn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced it has shipped the first commercial orders of its Aquadex SmartFlow™ system to Brazil, following approval from the Brazilian Health Surveillance Agency, commonly known as ANVISA. CHF Solutions has partnered with Bragenix Ltda, to serve patients in Brazil. These shipments expand the company's worldwide sales outreach into South America and the largest market in the region.

CHF Solutions Announces First Commercial Shipments of Aquadex Systems to Brazil, following Regulatory Approval

EDEN PRAIRIE, Minn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has shipped Aquadex™ product to medical facilities in Tennessee and South Carolina to treat critically ill patients suffering from COVID-19.

CHF Solutions Announces Deployment of Aquadex Systems to Hospitals in the Southeast to Treat COVID-19 Patients

EDEN PRAIRIE, Minn., Oct. 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a new technological advance to the Aquadex SmartFlow™ system to promote venous blood flow in the arm of a patient.

CHF Solutions Submits Patent Application to Improve Venous Blood Flow and Ultrafiltration Efficiency

CHF Solutions (CHFS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

News for CHF Solutions Stock (CHFS)